AuTNA I implant study for retinitis pigmentosa with minimal vision
Part of Eyes & vision, Genetic & congenital clinical trials.
This pilot study tests an implant called AuTNA I in adults with retinitis pigmentosa who currently have no or only very limited light perception. The goal is to see whether the implant can work safely and potentially improve vision in a carefully selected group of people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have a doctor-confirmed diagnosis of retinitis pigmentosa
- In the study eye, you have no light perception or only suspicious light perception
- Your eye scans (OCT) show inner retinal structure is intact, with no new blood-vessel growth (neovascularization) in the macula/choroid
- You must not have major eye problems that could interfere with surgery or testing (like retinal detachment, severe uveitis, severe corneal issues, etc.)
- You can take part safely: controlled general health, no pregnancy/lactation, and no recent participation in another trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.